COVID-19 SARS-CoV-2 anti-viral crude drug herbal medicine kampo medicine

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2022
Historique:
received: 28 10 2021
accepted: 07 03 2022
entrez: 15 4 2022
pubmed: 16 4 2022
medline: 16 4 2022
Statut: epublish

Résumé

Several traditional Japanese Kampo formulas are known to have inhibitory effects on infections with viruses that cause respiratory symptoms. Although some herbs and their components have been reported to suppress SARS-CoV-2 replication

Identifiants

pubmed: 35422704
doi: 10.3389/fphar.2022.804103
pii: 804103
pmc: PMC9002321
doi:

Types de publication

Journal Article

Langues

eng

Pagination

804103

Informations de copyright

Copyright © 2022 Kakimoto, Nomura, Nazmul, Kitagawa, Kanno, Ogawa-Ochiai, Ohge, Ito and Sakaguchi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Sci Rep. 2021 Sep 17;11(1):18581
pubmed: 34535740
Viruses. 2014 Apr 23;6(4):1861-75
pubmed: 24762393
Phytomedicine. 2007 Feb;14(2-3):96-101
pubmed: 17141491
BMJ. 2020 Nov 19;371:m4457
pubmed: 33214186
Acta Pharmacol Sin. 2020 Sep;41(9):1167-1177
pubmed: 32737471
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Phytomedicine. 2021 May;85:153242
pubmed: 33867046
Evid Based Complement Alternat Med. 2019 Dec 3;2019:3230906
pubmed: 31871477
Evid Based Complement Alternat Med. 2014;2014:187036
pubmed: 24778699
Lancet. 2015 May 2;385(9979):1729-1737
pubmed: 25640810
Lancet Respir Med. 2014 May;2(5):395-404
pubmed: 24815805
PLoS One. 2013;8(1):e55343
pubmed: 23372851
Yakugaku Zasshi. 2019;139(11):1417-1425
pubmed: 31685738
J Biosci. 2020;45:
pubmed: 32345772
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Drug Discov Ther. 2016;10(2):109-13
pubmed: 26902927
Viruses. 2021 Apr 02;13(4):
pubmed: 33918301
PLoS One. 2014 Aug 13;9(8):e104422
pubmed: 25119187
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1219-1224
pubmed: 32281328
Antiviral Res. 1999 Dec 31;44(3):193-200
pubmed: 10651070
Biocontrol Sci. 2021;26(3):177-180
pubmed: 34556620
Biochem Pharmacol. 2021 Jan;183:114302
pubmed: 33121927
Front Pharmacol. 2021 Jun 23;12:656246
pubmed: 34248620

Auteurs

Masaki Kakimoto (M)

Department of General Internal Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Toshihito Nomura (T)

Department of Infectious Disease, Hiroshima University Hospital, Hiroshima, Japan.
Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Tanuza Nazmul (T)

Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Hiroki Kitagawa (H)

Department of Infectious Disease, Hiroshima University Hospital, Hiroshima, Japan.

Keishi Kanno (K)

Department of General Internal Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Keiko Ogawa-Ochiai (K)

Department of General Internal Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Kampo Clinical Center, Department of General Internal Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Hiroki Ohge (H)

Department of Infectious Disease, Hiroshima University Hospital, Hiroshima, Japan.

Masanori Ito (M)

Department of General Internal Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Takemasa Sakaguchi (T)

Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Classifications MeSH